Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST 12:00 p.m. PST (PRNewsfoto/Nektar Therapeutics) Nektar's Chief Research & Development Officer, Jonathan Zalevsky , Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetes experts, including: Dr. Kevin Herold , TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University at Yale School of Medicine Dr. Megan Levings , Professor, Department of Surgery and School of Biomedical Engineering at The University Of British Columbia ; and, Dr. Daniel Moore , Associate Professor of Pediatrics and Pathology, Microbiology & Immunology at Vanderbilt University Medical Center. To access the conference call, please pre-r
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferencePR Newswire
- Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.MarketBeat
- Nektar Therapeutics (NASDAQ: NKTR) had its "market perform" rating re-affirmed by analysts at William Blair.MarketBeat
- Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.MarketBeat
- Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]Yahoo! Finance
NKTR
Earnings
- 3/12/25 - Beat
NKTR
Sec Filings
- 4/2/25 - Form EFFECT
- 3/28/25 - Form 8-K
- 3/28/25 - Form S-3
- NKTR's page on the SEC website